Jericho Capital Asset Management L.P. Revance Therapeutics, Inc. Transaction History

Jericho Capital Asset Management L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $9.24 Million - $17.7 Million	503,000 Added 53.76%	1,438,669 $46.3 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $4.06 Million - $6.8 Million	221,669 Added 31.05%	935,669 $17.3 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $10.2 Million - $20.3 Million	714,000 New	714,000 $19.3 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Jericho Capital Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Jericho Capital Asset Management L.P. with notifications on news.